×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
XBIO – xenetic biosciences, inc. (US:AMEX)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
XBIO
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
11/21
08:48 am
xbio
Xenetic Biosciences, Inc. Presents Positive Preclinical Data Highlighting the Potential of Co-Administration of DNase I with CAR T Cells in a Murine Model of Melanoma Lung Metastasis [Yahoo! Finance]
Medium
Report
Xenetic Biosciences, Inc. Presents Positive Preclinical Data Highlighting the Potential of Co-Administration of DNase I with CAR T Cells in a Murine Model of Melanoma Lung Metastasis [Yahoo! Finance]
11/21
08:30 am
xbio
Xenetic Biosciences, Inc. Presents Positive Preclinical Data Highlighting the Potential of Co-Administration of DNase I with CAR T Cells in a Murine Model of Melanoma Lung Metastasis
Medium
Report
Xenetic Biosciences, Inc. Presents Positive Preclinical Data Highlighting the Potential of Co-Administration of DNase I with CAR T Cells in a Murine Model of Melanoma Lung Metastasis
11/13
08:30 am
xbio
Xenetic Biosciences, Inc. Reports Third Quarter 2024 Financial Results
High
Report
Xenetic Biosciences, Inc. Reports Third Quarter 2024 Financial Results
11/12
09:00 am
xbio
Xenetic Biosciences, Inc. Presents Positive Data Demonstrating DNase I Significantly Improves Efficacy of Anti-CTLA-4 Immune Checkpoint Blockade in Preclinical Colorectal Carcinoma Models
Medium
Report
Xenetic Biosciences, Inc. Presents Positive Data Demonstrating DNase I Significantly Improves Efficacy of Anti-CTLA-4 Immune Checkpoint Blockade in Preclinical Colorectal Carcinoma Models
11/7
09:00 am
xbio
Xenetic Biosciences, Inc. Extends Research and Development Collaboration with The Scripps Research Institute to Advance DNase Platform
Low
Report
Xenetic Biosciences, Inc. Extends Research and Development Collaboration with The Scripps Research Institute to Advance DNase Platform
10/22
09:21 am
xbio
Xenetic Biosciences, Inc. Announces Abstract Accepted for Poster Presentation at Society for Immunotherapy of Cancer (SITC) 2024 [Yahoo! Finance]
Medium
Report
Xenetic Biosciences, Inc. Announces Abstract Accepted for Poster Presentation at Society for Immunotherapy of Cancer (SITC) 2024 [Yahoo! Finance]
10/22
08:45 am
xbio
Xenetic Biosciences, Inc. Announces Abstract Accepted for Poster Presentation at Society for Immunotherapy of Cancer (SITC) 2024
Low
Report
Xenetic Biosciences, Inc. Announces Abstract Accepted for Poster Presentation at Society for Immunotherapy of Cancer (SITC) 2024
10/17
09:02 am
xbio
Xenetic Biosciences, Inc. Enters into Materials Transfer Agreement with Tokyo Medical University for the Advancement of Its DNase-Based Oncology Platform [Yahoo! Finance]
Low
Report
Xenetic Biosciences, Inc. Enters into Materials Transfer Agreement with Tokyo Medical University for the Advancement of Its DNase-Based Oncology Platform [Yahoo! Finance]
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
11/13
08:30 am
xbio
Form 8-K Xenetic Biosciences, For: Nov 13
High
Report
Form 8-K Xenetic Biosciences, For: Nov 13
11/12
04:31 pm
xbio
Form 10-Q Xenetic Biosciences, For: Sep 30
High
Report
Form 10-Q Xenetic Biosciences, For: Sep 30
11/7
09:04 am
xbio
Form 8-K Xenetic Biosciences, For: Nov 01
Low
Report
Form 8-K Xenetic Biosciences, For: Nov 01
11/4
06:03 am
xbio
Form EFFECT Xenetic Biosciences,
High
Report
Form EFFECT Xenetic Biosciences,
10/31
05:00 pm
xbio
Form 8-K Xenetic Biosciences, For: Oct 29
Low
Report
Form 8-K Xenetic Biosciences, For: Oct 29
10/31
04:51 pm
xbio
Form ARS Xenetic Biosciences, For: Dec 31
Low
Report
Form ARS Xenetic Biosciences, For: Dec 31
10/31
04:41 pm
xbio
Form DEFA14A Xenetic Biosciences,
Low
Report
Form DEFA14A Xenetic Biosciences,
10/31
04:31 pm
xbio
Form DEF 14A Xenetic Biosciences, For: Dec 11
Low
Report
Form DEF 14A Xenetic Biosciences, For: Dec 11
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
7/5
Form S-1/A Xenetic Biosciences,
39.2%
6/24 Xenetic Biosciences, Inc. Announces Reverse Stock Split of Common Stock 31.6%
8/5 Form 3 Xenetic Biosciences, For: Jul 19 Filed by: VINOGRADOV ALEXEY ANDREEVICH 9.4%
4/24 Xenetic Biosciences (XBIO) Investor Presentation - Slideshow [Seeking Alpha] 8.9%
4/2 Form 4/A Xenetic Biosciences, For: Sep 26 Filed by: Borisenko Grigory G. 5.1%
7/25 Form SC 13G Xenetic Biosciences, Filed by: Altium Capital Management LP 4.9%
1/21 Form SC 13G/A Xenetic Biosciences, Filed by: Empery Asset Management, LP 4.8%
7/29 Form SC 13D Xenetic Biosciences, Filed by: Opko Health, Inc. 4.1%
9/4 Form SC 13G Xenetic Biosciences, Filed by: SABBY MANAGEMENT, LLC 3.5%
1/13 Form SC 13G/A Xenetic Biosciences, Filed by: SABBY MANAGEMENT, LLC 3.3%
6/24 Xenetic Biosciences, Inc. Announces Reverse Stock Split of Common Stock 31.6%
8/5 Form 3 Xenetic Biosciences, For: Jul 19 Filed by: VINOGRADOV ALEXEY ANDREEVICH 9.4%
4/24 Xenetic Biosciences (XBIO) Investor Presentation - Slideshow [Seeking Alpha] 8.9%
4/2 Form 4/A Xenetic Biosciences, For: Sep 26 Filed by: Borisenko Grigory G. 5.1%
7/25 Form SC 13G Xenetic Biosciences, Filed by: Altium Capital Management LP 4.9%
1/21 Form SC 13G/A Xenetic Biosciences, Filed by: Empery Asset Management, LP 4.8%
7/29 Form SC 13D Xenetic Biosciences, Filed by: Opko Health, Inc. 4.1%
9/4 Form SC 13G Xenetic Biosciences, Filed by: SABBY MANAGEMENT, LLC 3.5%
1/13 Form SC 13G/A Xenetic Biosciences, Filed by: SABBY MANAGEMENT, LLC 3.3%
TOP News Decliners
7/16
Form 8-K Xenetic Biosciences, For: Jul 16
-51.6%
7/22 Xenetic Biosciences, Inc. Closes $15.0 Million Underwritten Public Offering and Completes Acquisition of Innovative CAR T Technology Platform -30.7%
5/15 Form S-1 Xenetic Biosciences, -27.3%
7/22 Form 8-A12B Xenetic Biosciences, -19.1%
7/2 Form 8-K Xenetic Biosciences, For: Jun 28 -18.8%
7/12 Form S-1/A Xenetic Biosciences, -17.8%
7/29 Form SC 13G Xenetic Biosciences, Filed by: Anson Funds Management LP -14.6%
2/11 Xenetic Biosciences, Inc. to Present at Noble Capital Markets' 16th Annual Investor Conference -10.3%
10/16 Xenetic Biosciences, Inc. to Present at BIO Investor Forum -9.7%
11/15 Xenetic Biosciences, Inc. Reports Third Quarter 2019 Financial Results and Provides Corporate Update -9.5%
7/22 Xenetic Biosciences, Inc. Closes $15.0 Million Underwritten Public Offering and Completes Acquisition of Innovative CAR T Technology Platform -30.7%
5/15 Form S-1 Xenetic Biosciences, -27.3%
7/22 Form 8-A12B Xenetic Biosciences, -19.1%
7/2 Form 8-K Xenetic Biosciences, For: Jun 28 -18.8%
7/12 Form S-1/A Xenetic Biosciences, -17.8%
7/29 Form SC 13G Xenetic Biosciences, Filed by: Anson Funds Management LP -14.6%
2/11 Xenetic Biosciences, Inc. to Present at Noble Capital Markets' 16th Annual Investor Conference -10.3%
10/16 Xenetic Biosciences, Inc. to Present at BIO Investor Forum -9.7%
11/15 Xenetic Biosciences, Inc. Reports Third Quarter 2019 Financial Results and Provides Corporate Update -9.5%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: